Universal Beteiligungs und Servicegesellschaft mbH Has $21.83 Million Stock Holdings in Biogen Inc. $BIIB

Universal Beteiligungs und Servicegesellschaft mbH cut its position in shares of Biogen Inc. (NASDAQ:BIIB - Free Report) by 16.2% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 123,736 shares of the biotechnology company's stock after selling 23,908 shares during the quarter. Universal Beteiligungs und Servicegesellschaft mbH owned 0.08% of Biogen worth $21,834,000 at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in the company. Optas LLC grew its position in Biogen by 4.5% during the fourth quarter. Optas LLC now owns 1,706 shares of the biotechnology company's stock worth $300,000 after buying an additional 73 shares in the last quarter. Jones Kertz & Associates Inc. acquired a new stake in Biogen during the fourth quarter valued at approximately $790,000. Evergreen Capital Management LLC boosted its holdings in Biogen by 11.7% during the fourth quarter. Evergreen Capital Management LLC now owns 2,588 shares of the biotechnology company's stock valued at $455,000 after purchasing an additional 271 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in Biogen by 29.9% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 452,442 shares of the biotechnology company's stock valued at $79,625,000 after purchasing an additional 104,038 shares in the last quarter. Finally, Bayforest Capital Ltd boosted its holdings in Biogen by 106.8% during the fourth quarter. Bayforest Capital Ltd now owns 887 shares of the biotechnology company's stock valued at $156,000 after purchasing an additional 458 shares in the last quarter. 87.93% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

BIIB has been the topic of a number of recent research reports. Sanford C. Bernstein reaffirmed a "market perform" rating on shares of Biogen in a report on Monday, February 9th. Barclays initiated coverage on Biogen in a report on Thursday, February 19th. They set an "equal weight" rating and a $185.00 price objective on the stock. Canaccord Genuity Group lifted their price objective on Biogen from $230.00 to $245.00 and gave the company a "buy" rating in a report on Wednesday, April 1st. Guggenheim lifted their price objective on Biogen from $185.00 to $246.00 and gave the company a "buy" rating in a report on Monday, February 9th. Finally, Truist Financial decreased their price objective on Biogen from $193.00 to $189.00 and set a "hold" rating on the stock in a report on Monday, April 13th. Fourteen research analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of "Hold" and an average price target of $211.31.

Biogen Stock Down 1.9%

Shares of BIIB opened at $184.38 on Friday. The company has a market capitalization of $27.06 billion, a P/E ratio of 20.93, a PEG ratio of 2.51 and a beta of 0.16. The company has a debt-to-equity ratio of 0.34, a current ratio of 2.68 and a quick ratio of 2.03. Biogen Inc. has a one year low of $115.25 and a one year high of $202.41. The business's 50 day simple moving average is $185.13 and its 200-day simple moving average is $175.03.

Biogen (NASDAQ:BIIB - Get Free Report) last announced its earnings results on Friday, February 6th. The biotechnology company reported $1.99 EPS for the quarter, topping the consensus estimate of $1.61 by $0.38. The business had revenue of $2.28 billion for the quarter, compared to the consensus estimate of $2.21 billion. Biogen had a return on equity of 12.64% and a net margin of 13.07%.Biogen's revenue was down 7.2% compared to the same quarter last year. During the same period in the previous year, the business earned $3.44 EPS. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS. As a group, sell-side analysts predict that Biogen Inc. will post 15.77 EPS for the current fiscal year.

Insider Activity at Biogen

In other news, insider Priya Singhal sold 2,660 shares of the business's stock in a transaction that occurred on Monday, February 9th. The stock was sold at an average price of $199.83, for a total value of $531,547.80. Following the transaction, the insider directly owned 8,043 shares of the company's stock, valued at $1,607,232.69. The trade was a 24.85% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.18% of the stock is owned by insiders.

Key Stories Impacting Biogen

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Biogen struck a China deal to develop felzartamab as a domestically produced anti‑CD38 therapy for multiple myeloma — this expands its China footprint and could open a meaningful growth market. Biogen seeks Darzalex rivalry in China for multiple myeloma with felzartamab deal
• Positive Sentiment: UBS upgraded Biogen, and JPMorgan raised its price target to $185 (still a Neutral rating) — these moves provide some analyst validation for the story but stop short of a full buy case. UBS upgrades Biogen (BIIB) JPMorgan raises price target
• Neutral Sentiment: Q1 earnings preview pieces highlight that new products (Skyclarys, Zurzuvae) are driving growth but legacy MS sales face competitive pressure — outcome of Q1 will be a key catalyst and remains uncertain. Biogen Q1 Earnings: Can New Launches Offset Declining MS Franchise?
• Neutral Sentiment: Rothschild & Co Redburn issued EPS estimates and raised its price target to $180 while maintaining a Neutral rating — adds supply of modeled forecasts but not a bullish call. Rothschild & Co Redburn estimates and target
• Negative Sentiment: Short interest rose to ~4.41M shares as of April 15 (+15.4% vs. March 31), representing about 3.0% of float and a short‑interest ratio ~3.1 days — higher shorting can amplify downward pressure around weak news. (Note: an April 24 data point showing zero shares appears to be a reporting anomaly.)
• Negative Sentiment: Wolfe Research trimmed Q1 and Q2 EPS estimates (and trimmed Q2 guidance), signaling risk to near‑term earnings expectations and likely contributing to negative trading sentiment.

Biogen Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer's disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company's marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.

Want to see what other hedge funds are holding BIIB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Biogen Inc. (NASDAQ:BIIB - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.